+

US20180007924A9 - Homogenous cannabis compositions and methods of making the same - Google Patents

Homogenous cannabis compositions and methods of making the same Download PDF

Info

Publication number
US20180007924A9
US20180007924A9 US15/084,954 US201615084954A US2018007924A9 US 20180007924 A9 US20180007924 A9 US 20180007924A9 US 201615084954 A US201615084954 A US 201615084954A US 2018007924 A9 US2018007924 A9 US 2018007924A9
Authority
US
United States
Prior art keywords
composition
oil
cannabis
cannabinoid
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/084,954
Other versions
US20170280740A1 (en
Inventor
Jeremy H. Goldstein
Justin Eric Singer
Adrian Verwolf
Garret Nicodemus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
5071 Inc
Original Assignee
5071 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2985332A priority Critical patent/CA2985332C/en
Priority to US15/084,954 priority patent/US20180007924A9/en
Priority to CA3176674A priority patent/CA3176674A1/en
Priority to PCT/US2016/025044 priority patent/WO2016186735A1/en
Assigned to 5071, INC. reassignment 5071, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GOLDSTEIN, Jeremy H., SINGER, Justin Eric
Application filed by 5071 Inc filed Critical 5071 Inc
Assigned to 5071, INC. reassignment 5071, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NICODEMUS, GARRET, VERWOLF, Adrian
Publication of US20170280740A1 publication Critical patent/US20170280740A1/en
Publication of US20180007924A9 publication Critical patent/US20180007924A9/en
Priority to US16/571,610 priority patent/US11980204B2/en
Priority to US18/340,572 priority patent/US12225913B2/en
Priority to US18/963,286 priority patent/US20250089735A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23FCOFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00Tea; Tea substitutes; Preparations thereof
    • A23F3/06Treating tea before extraction; Preparations produced thereby
    • A23F3/14Tea preparations, e.g. using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00Shaping or working of foodstuffs characterised by the products
    • A23P10/40Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1658Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1664Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This disclosure relates to the cannabis industry.
  • the disclosure relates to cannabis compositions for use in the making beverages, methods of making beverages, and beverages.
  • Cannabis has a long history of being consumed for many purposes and in many forms.
  • the psychoactive effects of cannabis are well known, however the medical benefits are just as useful. Treating glaucoma, pain management, appetite stimulation and easing anxiety are just a few of the potential benefits.
  • the source of these effects are in the cannabinoids, a class of compounds found exclusively in the cannabis plant.
  • cannabinoids a class of compounds found exclusively in the cannabis plant.
  • THC tetrahydrocannabniol
  • CBD cannabidiol
  • CBD is also another major cannabinoid comprising up to 40% of cannabis extract and could have as many health benefits as THC.
  • a common method is alcohol extraction. Using a solvent to extract the cannabinoids and then evaporating the alcohol leaving a resin. Further extraction and evaporation can yield a product that is closer to a solid.
  • Another common method for the purposes of making edibles is placing the cannabis leaves in butter, heavy cream, oil, etc and then heating to extract the cannabinoids. The end product is then used as an ingredient in baking or cooking which usually results in a high caloric food due to the fat needed to extract the cannabinoids.
  • Cannabinoids are soluble in fats and alcohols. Which is why when making cannabis tea the cannabinoids have to be already extracted. Just placing cannabis leaves in hot water will not effectively extract any of the vital cannabinoids.
  • the cannabis arts do not have homogenous cannabis beverages.
  • Existing cannabis beverages include large amounts of caloric material.
  • Existing cannabis beverages are not capable of providing consistent cannabinoid concentrations, especially at low cannabinoid concentrations.
  • these new cannabis compositions are beverages, such as tea.
  • these new cannabis compositions are dehydrated beverages, such as powders or crystalline forms, which can be mixed with other components, like tea, and added to water.
  • the disclosed cannabis compositions are homogenous. In one embodiment, the disclosed cannabis compositions include a surfactant and a carrier oil. In one embodiment, the disclosed cannabis compositions are consistent with respect to cannabinoid amount. In one embodiment, the disclosed cannabis compositions are low-calorie cannabis beverages, such as low calorie cannabis teas.
  • compositions comprising:
  • cannabinoid refers to a compound that acts on the cannabinoid receptor.
  • the compositions are low does compositions having 0.1 to 10 mg of cannabinoid. In some embodiments, the composition comprises between 0.5 to 5 mg.
  • cannabinoid can be used, such as more than 10 mg, for example 20-500 mg or 50-200 mg.
  • cannabinoids are tetrahydrocannabinol, cannabidiol, cannabigerol, cannabichromene, cannabicyclol, cannabivarin, cannabielsoin, cannabicitran, cannabigerolic acid, cannabigerolic acid monomethylether, cannabigerol monomethylether, cannabigerovarinic acid, cannabigerovarin, cannabichromenic acid, cannabichromevarinic acid, cannabichromevarin, cannabidolic acid, cannabidiol monomethylether, cannabidiol-C 4 , cannabidivarinic acid, cannabidiorcol, delta-9-tetrahydrocannabinolic acid A, delta-9-tetrahydrocannabinolic
  • THC tetrahydrocannabinol
  • CBD canbidiol
  • surfactant refers to a compound that lowers the surface tension between two liquids or between a liquid and solid.
  • Surfactants can be anionic, cationic, non-ionic and amphoteric.
  • Examples of surfactants are ammonium lauryl sulfate, dioctyl sodium sulfosuccinate, perflurooctanoic acid, potassium lauryl sulfate, soap, sodium dodecyl sulfate, sodium dodecylbenzenesulfonate, sodium laureth sulfate, sodium lauroyl sarcosinate, sodium myreth sulfate, sodium pareth sulfate, sodium stearate, perflurobutanesulfonic acid, perfluorononanoic acid, perlurooactanesulfonic acid, benzalkonium chloride, benzethonium chloride, bronidox, dimethyldioctade
  • polysorbate 80 refers to a compound having the following structure:
  • glycol monostearate refers to a compound having the following structure:
  • carrier oil refers to an oil that can be used to form a homogenized mixture with cannabis oil. Examples include coconut oil, palm oil, palm kernel oil, hemp oil, caproic acid and caprylic acid.
  • carrier oils within the context of this disclosure is medium chain triglycerides.
  • coconut oil is another example of a carrier oil within the context of this disclosure.
  • hemp oil is another example of a carrier oil within the context of this disclosure.
  • coconut oil means oil extracted from the kernel or meat of coconuts.
  • coconut is the fruit of the coconut palm.
  • coconut oil is noted for it's high saturated content. Examples include lauric acid, myristic acid, palmitic acid, and decanoic acid.
  • hemp oil refers to oil obtained from hemp seeds. Hemp seeds come from a variety of the Cannabis sativa plant that does not contain a high amount of tetrahydrocannabinol.
  • the oil is about 80% essential fatty acids. Examples include linolenic acid, omega-6, alpha-linolenic acid, and omega-3.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and a sugar alcohol.
  • sugar alcohol refers to alcohols prepared from sugars with the general chemical formula HOCH 2 (CHOH) n CH 2 OH.
  • examples include glycerol, erythritol, threitol, arabitol, xylitol, mannitol, ribitol, mannitol, galacitol, fucitol, inositol, volemitol, maltitol, lacitol, malootetraitol, polyglycitol, sorbitol, iditol, isomalt, and maltotriitol.
  • sugar alcohols within the context of this disclosure include glycerol/glycerin or sorbitol.
  • glycol refers to a compound having the following structure:
  • sorbitol refers to a compound having the following structure:
  • the composition disclosed herein comprises a cannabinoid, a surfactant, a carrier oil, and a gelling agent.
  • gelling agent means a substance that dissolves in the liquid phase and forms a weak cohesive internal structure. Examples include natural gums, starches, pectins, agar-agar, and gelatin.
  • gelatin refers to a gelling agent derived from the collagen of various all byproducts.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and has less than 10 mass % water. In one embodiment, the composition is a solid. In one embodiment, the composition is a granual.
  • the term “less than 10 mass % water” means less than 10% of water, by mass, of the composition.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and has more than 95 mass % water.
  • the term “more than 95 mass % water” means less than 95% of water, by mass, of the composition.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and a flavoring agent.
  • flavoring agent means a compound that adds a flavor to a composition.
  • flavoring agents include amyl acetate, benzaldehyde, ethyl butyrate, methyl anthranilate, methyl salicylate, fumaric acid, diacetyl, cinnamaldehyde, ethyl propionate, limonene, ethyl decadienoate, allyl hexanoate, ethyl maltol, ethylvanillin, and methyl salicylate.
  • the composition comprises a coloring agent.
  • coloring agent means any substance that adds or changes the color of the substance to which the coloring agent is added.
  • examples of the term coloring agent include any dye, pigment or substance that imparts color when it is added to food or drink.
  • the coloring agent can be natural or non-natural. Such agents come in many forms, including liquids, powders, gels, dyes, lakes, and pastes.
  • one or more coloring agents can be added to the compositions of this disclosure to match the coloring between two ingredients.
  • brownish color is added to a compositions comprising a cannabinoid, a surfactant, and a carrier oil in order to make the said compositions take on the color of natural tea.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and tea.
  • tea are tea leaves.
  • tea is meant to include any composition that is similar or labeled as tea, either natural or synthetic. Tea refers to both artificially flavored and/or artificially colored compositions in addition to all forms of natural tea leaves.
  • the cannabis compositions are brown granules.
  • leaf refers to forms of the plant Camellia sinensis.
  • the composition comprises less than 4 grams of caloric mass. In one embodiment the caloric mass is less than 2 grams.
  • caloric mass means mass metabolized by humans to generate energy. Examples include carbohydrates and proteins which give 4 cal/gram and fats which give 9 cal/gram.
  • the composition comprises 0.5 to 5 mg of the cannabinoid is present in a consistent amount, having less than 0.2 mg of deviation across sample portions of the composition.
  • the term“consistent amount” means a collection of samples would all have relatively similar amounts of the cannabinoid. Similar means limited amount of deviation in the mass of the cannabinoid. For example, if a collection of compositions were analyzed to determine the mass of cannabinoid present, each sample in that collection would have a similar mass of cannabinoid present in relation to the total amount of each composition.
  • the composition comprises:
  • the gram amounts of ingredients depend on the batch size. Gram amounts for batches can be determined by following the mixing guidelines below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Disclosed herein are new cannabis compositions. In one embodiment, these new cannabis compositions are beverages, such as tea. In one embodiment, these new cannabis compositions are dehydrated beverages, such as powders or crystalline forms, which can be mixed with other components, like tea, and added to water.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application No. 62/163,316, filed May 18, 2015, the disclosure of which is incorporated herein by reference.
  • TECHNICAL FIELD
  • This disclosure relates to the cannabis industry. In particular, the disclosure relates to cannabis compositions for use in the making beverages, methods of making beverages, and beverages.
  • BACKGROUND
  • Cannabis has a long history of being consumed for many purposes and in many forms. The psychoactive effects of cannabis are well known, however the medical benefits are just as useful. Treating glaucoma, pain management, appetite stimulation and easing anxiety are just a few of the potential benefits. The source of these effects are in the cannabinoids, a class of compounds found exclusively in the cannabis plant. Currently there are 483 identified compounds found in cannabis. The most well known, and in some ways the most important, is tetrahydrocannabniol (THC). THC is responsible for many of the psychoactive effects as well as the medicinal effects. Cannabidiol (CBD) is also another major cannabinoid comprising up to 40% of cannabis extract and could have as many health benefits as THC.
  • Many methods exist for extracting the cannabinoids from the cannabis plant. A common method is alcohol extraction. Using a solvent to extract the cannabinoids and then evaporating the alcohol leaving a resin. Further extraction and evaporation can yield a product that is closer to a solid. Another common method for the purposes of making edibles is placing the cannabis leaves in butter, heavy cream, oil, etc and then heating to extract the cannabinoids. The end product is then used as an ingredient in baking or cooking which usually results in a high caloric food due to the fat needed to extract the cannabinoids. Cannabinoids are soluble in fats and alcohols. Which is why when making cannabis tea the cannabinoids have to be already extracted. Just placing cannabis leaves in hot water will not effectively extract any of the vital cannabinoids.
  • However, the state of the art has many shortcomings. The cannabis arts do not have homogenous cannabis beverages. Existing cannabis beverages include large amounts of caloric material. Existing cannabis beverages are not capable of providing consistent cannabinoid concentrations, especially at low cannabinoid concentrations.
  • There exists a need for homogenous cannabis beverages. In particular there exists a need for beverages providing a consistent amount of the cannabinoid, especially at low doses.
  • DETAILED DESCRIPTION
  • Disclosed herein are new cannabis compositions. In one embodiment, these new cannabis compositions are beverages, such as tea. In one embodiment, these new cannabis compositions are dehydrated beverages, such as powders or crystalline forms, which can be mixed with other components, like tea, and added to water.
  • In one embodiment, the disclosed cannabis compositions are homogenous. In one embodiment, the disclosed cannabis compositions include a surfactant and a carrier oil. In one embodiment, the disclosed cannabis compositions are consistent with respect to cannabinoid amount. In one embodiment, the disclosed cannabis compositions are low-calorie cannabis beverages, such as low calorie cannabis teas.
  • Disclosed herein are new compositions comprising:
      • a cannabinoid,
      • a surfactant, and
      • a carrier oil.
  • As used herein the term “cannabinoid” refers to a compound that acts on the cannabinoid receptor. In one embodiment of this disclosure, the compositions are low does compositions having 0.1 to 10 mg of cannabinoid. In some embodiments, the composition comprises between 0.5 to 5 mg.
  • In other embodiments of this disclosure, higher amounts of cannabinoid can be used, such as more than 10 mg, for example 20-500 mg or 50-200 mg. Examples of cannabinoids are tetrahydrocannabinol, cannabidiol, cannabigerol, cannabichromene, cannabicyclol, cannabivarin, cannabielsoin, cannabicitran, cannabigerolic acid, cannabigerolic acid monomethylether, cannabigerol monomethylether, cannabigerovarinic acid, cannabigerovarin, cannabichromenic acid, cannabichromevarinic acid, cannabichromevarin, cannabidolic acid, cannabidiol monomethylether, cannabidiol-C4, cannabidivarinic acid, cannabidiorcol, delta-9-tetrahydrocannabinolic acid A, delta-9-tetrahydrocannabinolic acid B, delta-9-tetrahydrocannabinolic acid-C4, delta-9-tetrahydrocannabivarinic acid, delta-9-tetrahydrocannabivarin, delta-9-tetrahydrocannabiorcolic acid, delta-9-tetrahydrocannabiorcol, delta-7-cis-iso-tetrahydrocannabivarin, delta-8-tetrahydrocannabiniolic acid, delta-8-tetrahydrocannabinol, cannabicyclolic acid, cannabicylovarin, cannabielsoic acid A, cannabielsoic acid B, cannabinolic acid, cannabinol methylether, cannabinol-C4, cannabinol-C2, cannabiorcol, 10-ethoxy-9-hydroxy-delta-6a-tetrahydrocannabinol, 8,9-dihydroxy-delta-6a-tetrahydrocannabinol, cannabitriolvarin, ethoxy-cannabitriolvarin, dehydrocannabifuran, cannabifuran, cannabichromanon, cannabicitran, 10-oxo-delta-6a-tetrahydrocannabinol, delta-9-cis-tetrahydrocannabinol, 3,4,5,6-tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol-cannabiripsol, trihydroxy-delta-9-tetrahydrocannabinol, and cannabinol. Examples of cannabinoids within the context of this disclosure include tetrahydrocannabinol and cannabidiol.
  • As used herein, the term “tetrahydrocannabinol” (THC) refers to a compound having the following structural formula:
  • Figure US20180007924A9-20180111-C00001
  • As used herein, the term “cannabidiol” (CBD) refers to a compound having the following structural formula:
  • Figure US20180007924A9-20180111-C00002
  • As used herein the term “surfactant” refers to a compound that lowers the surface tension between two liquids or between a liquid and solid. Surfactants can be anionic, cationic, non-ionic and amphoteric. Examples of surfactants are ammonium lauryl sulfate, dioctyl sodium sulfosuccinate, perflurooctanoic acid, potassium lauryl sulfate, soap, sodium dodecyl sulfate, sodium dodecylbenzenesulfonate, sodium laureth sulfate, sodium lauroyl sarcosinate, sodium myreth sulfate, sodium pareth sulfate, sodium stearate, perflurobutanesulfonic acid, perfluorononanoic acid, perlurooactanesulfonic acid, benzalkonium chloride, benzethonium chloride, bronidox, dimethyldioctadecylammonium chloride, lauryl methyl gluceth-10 hydroxypropyl dimonium chloride, cetrimonium bromide, cetrimonium chloride, tetramethylammonium hydroxide, cetomacrogol 1000, cetostearyl alcohol, cetyl alcohol, cocamide DEA, cocamide MEA, NP-40, octaethylene glycol monododecyl ether, N-octyl beta-D-thoglucopyranoside, octyl glucoside, oleyl alcohol, decyl glucoside, pentaethylene glycol monododecyl ether, poloxamer 407, polyglycerol polyricinolate, polysorbate, polysorabte 20, IGEPAL CA-630, isoceteth-20, lauryl glucoside, lecithin, sodium lauroampoacetate, cocamidopropyl betaine, hydroxysultaine, stearyl alcohol, decyl glucoside, octaethylene glycol monododecyl ether, nonoxynol-9, monolaurin, oleyl alcohol, poloxamer, sorbitan monostearate, polysorbate 80 and glycerol monostearate. Examples of surfactants within the context of this disclosure include polysorbate 80 and/or glycerol monostearate.
  • As used herein, the term “polysorbate 80” refers to a compound having the following structure:
  • Figure US20180007924A9-20180111-C00003
  • As used herein the term “glycerol monostearate” refers to a compound having the following structure:
  • Figure US20180007924A9-20180111-C00004
  • As used herein the term “carrier oil” refers to an oil that can be used to form a homogenized mixture with cannabis oil. Examples include coconut oil, palm oil, palm kernel oil, hemp oil, caproic acid and caprylic acid. One example of carrier oils within the context of this disclosure is medium chain triglycerides. Another example of a carrier oil within the context of this disclosure is coconut oil. Another example of a carrier oil within the context of this disclosure is hemp oil.
  • As used herein the term coconut oil means oil extracted from the kernel or meat of coconuts. Coconut is the fruit of the coconut palm. Coconut oil is noted for it's high saturated content. Examples include lauric acid, myristic acid, palmitic acid, and decanoic acid.
  • As used herein the term hemp oil refers to oil obtained from hemp seeds. Hemp seeds come from a variety of the Cannabis sativa plant that does not contain a high amount of tetrahydrocannabinol. The oil is about 80% essential fatty acids. Examples include linolenic acid, omega-6, alpha-linolenic acid, and omega-3. In one embodiment, the composition comprises a cannabinoid, a surfactant, a carrier oil, and a sugar alcohol.
  • As used herein the term “sugar alcohol” refers to alcohols prepared from sugars with the general chemical formula HOCH2(CHOH)nCH2OH. Examples include glycerol, erythritol, threitol, arabitol, xylitol, mannitol, ribitol, mannitol, galacitol, fucitol, inositol, volemitol, maltitol, lacitol, malootetraitol, polyglycitol, sorbitol, iditol, isomalt, and maltotriitol. Examples of sugar alcohols within the context of this disclosure include glycerol/glycerin or sorbitol.
  • As used herein, the term “glycerol” refers to a compound having the following structure:
  • Figure US20180007924A9-20180111-C00005
  • As used herein, the term “sorbitol” refers to a compound having the following structure:
  • Figure US20180007924A9-20180111-C00006
  • In one embodiment, the composition disclosed herein comprises a cannabinoid, a surfactant, a carrier oil, and a gelling agent.
  • As used herein, the term “gelling agent” means a substance that dissolves in the liquid phase and forms a weak cohesive internal structure. Examples include natural gums, starches, pectins, agar-agar, and gelatin.
  • As used herein, the term “gelatin” refers to a gelling agent derived from the collagen of various all byproducts.
  • In one embodiment, the composition comprises a cannabinoid, a surfactant, a carrier oil, and has less than 10 mass % water. In one embodiment, the composition is a solid. In one embodiment, the composition is a granual.
  • As used herein, the term “less than 10 mass % water” means less than 10% of water, by mass, of the composition.
  • In one embodiment, the composition comprises a cannabinoid, a surfactant, a carrier oil, and has more than 95 mass % water.
  • As used herein, the term “more than 95 mass % water” means less than 95% of water, by mass, of the composition.
  • In one embodiment, the composition comprises a cannabinoid, a surfactant, a carrier oil, and a flavoring agent.
  • As used herein, the term “flavoring agent” means a compound that adds a flavor to a composition. A few examples of flavoring agents include amyl acetate, benzaldehyde, ethyl butyrate, methyl anthranilate, methyl salicylate, fumaric acid, diacetyl, cinnamaldehyde, ethyl propionate, limonene, ethyl decadienoate, allyl hexanoate, ethyl maltol, ethylvanillin, and methyl salicylate.
  • In one embodiment, the composition comprises a coloring agent. As used herein, the term “coloring agent” means any substance that adds or changes the color of the substance to which the coloring agent is added. Within the context of this application, examples of the term coloring agent include any dye, pigment or substance that imparts color when it is added to food or drink. The coloring agent can be natural or non-natural. Such agents come in many forms, including liquids, powders, gels, dyes, lakes, and pastes. In one exemplary embodiment, one or more coloring agents can be added to the compositions of this disclosure to match the coloring between two ingredients. In one example, brownish color is added to a compositions comprising a cannabinoid, a surfactant, and a carrier oil in order to make the said compositions take on the color of natural tea.
  • In one embodiment, the composition comprises a cannabinoid, a surfactant, a carrier oil, and tea. In one embodiment the tea are tea leaves. As used herein, the term “tea” is meant to include any composition that is similar or labeled as tea, either natural or synthetic. Tea refers to both artificially flavored and/or artificially colored compositions in addition to all forms of natural tea leaves. In one embodiment, the cannabis compositions are brown granules.
  • As used herein the term “tea leaves” refers to forms of the plant Camellia sinensis.
  • In one embodiment, the composition comprises less than 4 grams of caloric mass. In one embodiment the caloric mass is less than 2 grams. As the herein the term “caloric mass” means mass metabolized by humans to generate energy. Examples include carbohydrates and proteins which give 4 cal/gram and fats which give 9 cal/gram.
  • In one embodiment, the composition comprises 0.5 to 5 mg of the cannabinoid is present in a consistent amount, having less than 0.2 mg of deviation across sample portions of the composition.
  • As used herein the term“consistent amount” means a collection of samples would all have relatively similar amounts of the cannabinoid. Similar means limited amount of deviation in the mass of the cannabinoid. For example, if a collection of compositions were analyzed to determine the mass of cannabinoid present, each sample in that collection would have a similar mass of cannabinoid present in relation to the total amount of each composition.
  • In one embodiment, the composition comprises:
      • cannabis oil having 1.5 to 3.5 mg of THC;
      • glycerine,
      • sorbitol,
      • gelatin,
      • glycerol monostearate,
      • polysorbate 80, and
      • coconut oil.
        In one embodiment, the composition comprises:
      • cannabis oil having 1.5 to 3.5 mg of THC;
      • glycerine,
      • sorbitol,
      • gelatin,
      • glycerol monostearate,
      • polysorbate 80,
      • coconut oil, and
      • tea.
        In one embodiment, the composition comprises:
      • cannabis oil having 1.5 to 3.5 mg of THC;
      • glycerine,
      • sorbitol,
      • gelatin,
      • glycerol monostearate,
      • polysorbate 80,
      • coconut oil,
      • and greater than 95 mass % of water.
        In one embodiment, the composition comprises:
      • cannabis oil having 1.5 to 3.5 mg of THC;
      • glycerine,
      • sorbitol,
      • gelatin,
      • glycerol monostearate,
      • polysorbate 80,
      • coconut oil,
      • and less than 5 mass % of water.
    EXAMPLES
  • Although the present invention herein has been described with reference to various exemplary embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. Those having skill in the art would recognize that various modifications to the exemplary embodiments may be made, without departing from the scope of the invention.
  • Moreover, it should be understood that various features and/or characteristics of differing embodiments herein may be combined with one another. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the scope of the invention.
  • Furthermore, other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a scope and spirit being indicated by the claims.
  • Finally, it is noted that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the,” include plural referents unless expressly and unequivocally limited to one referent, and vice versa. As used herein, the term “include” or “comprising” and its grammatical variants are intended to be non-limiting, such that recitation of an item or items is not to the exclusion of other like items that can be substituted or added to the recited item(s).
  • The gram amounts of ingredients depend on the batch size. Gram amounts for batches can be determined by following the mixing guidelines below.
  • Ingredient Parts
    Water  8-12
    Surfactant 1-1.5
    Carrier Oil 4
    Cannabinoid 1
    Sugar alcohol 30-70
    Gelling agent 0.3-0.5
  • Example 1
      • 1) Surfactants were added to a beaker and heated to 80 C with a hot plate for 10 minutes to provide a homogeneous surfactant blend.
      • 2) Carrier oil and cannabis oil were added to the surfactant blend and stirred for 10 minutes at 60 C, to provide a homogenous mixture.
      • 3) A first sugar alcohol and gelling agent were added to water at 40 C. The mixture was heated to 80 C.
      • 4) A second sugar alcohol was added to the mixture of sugar alcohol and gelling agent over the course of 5 minutes and mixed until well blended.
      • 5) The sugar blend was added to the mixture of cannabis oil, carrier oil and surfactant blend over 10 minutes and the combined mixture was heated to 80 C to provide a homogenize mixture with no phase separation.
      • 6) The homogenized mixture was poured into trays, to create thin films, which were refrigerated for 60 minutes.
      • 7) After cooling for 60 minutes, the films were place in a dehydrator at 40 C.
      • 8) The films were dried for 24 hours, to provide brittle, dry films.
      • 9) The dry films were broken into smaller pieces.
      • 10) 10 gram portions of the broken dried films were separated by size with a sieve to remove particles less than 15 mesh size.
      • 11) The collected particles were placed into a vacuum oven set to 40 C for 24 hrs, to provide finished dry granules.
    Example 2
      • 1) Glycerol monostearate and polysorbate 80 were added to a beaker and heated to 80 C with a hot plate for 10 minutes to provide a homogeneous surfactant blend.
      • 2) Carrier and cannabis oil were added to the surfactant blend and stirred for 10 minutes at 60 C, to provide a homogenous mixture.
      • 3) Glycerin and gelatin were added to water at 40 C. The mixture was heated to 80 C.
      • 4) Sorbitol was added to the mixture of glycerin and gelatin over the course of 5 minutes and mixed until well blended.
      • 5) The blend of sorbitol, glycerine, and gelatin was added to the mixture of cannabis oil, coconut oil, glycerol monostearate, and polysorbate 80 over 10 minutes and the combined mixture was heated to 80 C to provide a homogenize mixture with no phase separation.
      • 6) The homogenized mixture was poured into trays, to create thin films, which were refrigerated for 60 minutes.
      • 7) After cooling for 60 minutes, the films were place in a dehydrator at 40 C.
      • 8) The films were dried for 24 hours, to provide brittle, dry films.
      • 9) The dry films were broken into smaller pieces.
      • 10) 10 gram portions of the broken dried films were separated by size with a sieve to remove particles less than 15 mesh size.
      • 11) The collected particles were placed into a vacuum oven set to 40 C for 24 hrs, to provide finished dry granules.
    Example 3
      • 1) Surfactants were added to a beaker and heated to 80 C with a hot plate for 10 minutes to provide a homogeneous surfactant blend.
      • 2) Carrier oil and CBD oil were added to the surfactant blend and stirred for 10 minutes at 60 C, to provide a homogenous mixture.
      • 3) A first sugar alcohol and gelling agent were added to water at 40 C. The mixture was heated to 80 C.
      • 4) A second sugar alcohol was added to the mixture of sugar alcohol and gelling agent over the course of 5 minutes and mixed until well blended.
      • 5) The sugar blend was added to the mixture of CBD oil, carrier oil and surfactant blend over 10 minutes and the combined mixture was heated to 80 C to provide a homogenize mixture with no phase separation.
      • 6) The homogenized mixture was poured into trays, to create thin films, which were refrigerated for 60 minutes.
      • 7) After cooling for 60 minutes, the films were place in a dehydrator at 40 C.
      • 8) The films were dried for 24 hours, to provide brittle, dry films.
      • 9) The dry films were broken into smaller pieces.
      • 10) 10 gram portions of the broken dried films were separated by size with a sieve to remove particles less than 15 mesh size.
      • 11) The collected particles were placed into a vacuum oven set to 40 C for 24 hrs, to provide finished dry granules.
    Example 4
      • 1) Surfactants were added to a beaker and heated to 80 C with a hot plate for 10 minutes to provide a homogeneous surfactant blend.
      • 2) Coconut oil and cannabis oil were added to the surfactant blend and stirred for 10 minutes at 60 C, to provide a homogenous mixture.
      • 3) A first sugar alcohol and gelling agent were added to water at 40 C. The mixture was heated to 80 C.
      • 4) A second sugar alcohol was added to the mixture of sugar alcohol and gelling agent over the course of 5 minutes and mixed until well blended.
      • 5) The sugar blend was added to the mixture of cannabis oil, coconut oil and surfactant blend over 10 minutes and the combined mixture was heated to 80 C to provide a homogenize mixture with no phase separation.
      • 6) The homogenized mixture was poured into trays, to create thin films, which were refrigerated for 60 minutes.
      • 7) After cooling for 60 minutes, the films were place in a dehydrator at 40 C.
      • 8) The films were dried for 24 hours, to provide brittle, dry films.
      • 9) The dry films were broken into smaller pieces.
      • 10) 10 gram portions of the broken dried films were separated by size with a sieve to remove particles less than 15 mesh size.
      • 11) The collected particles were placed into a vacuum oven set to 40 C for 24 hrs, to provide finished dry granules.
    Example 5
      • 1) Surfactants were added to a beaker and heated to 80 C with a hot plate for 10 minutes to provide a homogeneous surfactant blend.
      • 2) Hemp oil and cannabis oil were added to the surfactant blend and stirred for 10 minutes at 60 C, to provide a homogenous mixture.
      • 3) A first sugar alcohol and gelling agent were added to water at 40 C. The mixture was heated to 80 C.
      • 4) A second sugar alcohol was added to the mixture of sugar alcohol and gelling agent over the course of 5 minutes and mixed until well blended.
      • 5) The sugar blend was added to the mixture of cannabis oil, hemp oil and surfactant blend over 10 minutes and the combined mixture was heated to 80 C to provide a homogenize mixture with no phase separation.
      • 6) The homogenized mixture was poured into trays, to create thin films, which were refrigerated for 60 minutes.
      • 7) After cooling for 60 minutes, the films were place in a dehydrator at 40 C.
      • 8) The films were dried for 24 hours, to provide brittle, dry films.
      • 9) The dry films were broken into smaller pieces.
      • 10) 10 gram portions of the broken dried films were separated by size with a sieve to remove particles less than 15 mesh size.
      • 11) The collected particles were placed into a vacuum oven set to 40 C for 24 hrs, to provide finished dry granules.
    Example 6
      • 1) Surfactants were added to a beaker and heated to 80 C with a hot plate for 10 minutes to provide a homogeneous surfactant blend.
      • 2) Carrier oil and cannabis oil were added to the surfactant blend and stirred for 10 minutes at 60 C, to provide a homogenous mixture.
      • 3) A first sugar alcohol and gelatin were added to water at 40 C. The mixture was heated to 80 C.
      • 4) A second sugar alcohol was added to the mixture of sugar alcohol and gelatin over the course of 5 minutes and mixed until well blended.
      • 5) The sugar blend was added to the mixture of cannabis oil, carrier oil and surfactant blend over 10 minutes and the combined mixture was heated to 80 C to provide a homogenize mixture with no phase separation.
      • 6) The homogenized mixture was poured into trays, to create thin films, which were refrigerated for 60 minutes.
      • 7) After cooling for 60 minutes, the films were place in a dehydrator at 40 C.
      • 8) The films were dried for 24 hours, to provide brittle, dry films.
      • 9) The dry films were broken into smaller pieces.
      • 10) 10 gram portions of the broken dried films were separated by size with a sieve to remove particles less than 15 mesh size.
      • 11) The collected particles were placed into a vacuum oven set to 40 C for 24 hrs, to provide finished dry granules.
    Example 7
  • To make 2300 tea sticks
      • 1) 67 grams of glycerol monostearate and 40 grams of polysorbate 80 were added to a beaker and heated to 80 C with a hot plate for 10 minutes to provide a homogeneous surfactant blend.
      • 2) 341 grams of coconut oil and 85 grams of THC oil were added to the surfactant blend and stirred for 10 minutes at 60 C, to provide a homogenous mixture.
      • 3) 213 grams of glycerin and 32 grams of gelatin were added to 852 grams of water at 40 C. The mixture was heated to 80 C.
      • 4) 4259 grams of sorbitol was added to the mixture of glycerin and gelatin over the course of 5 minutes and mixed until well blended.
      • 5) The sugar blend was added to the mixture of THC oil, coconut oil and surfactant blend over 10 minutes and the combined mixture was heated to 80 C to provide a homogenize mixture with no phase separation.
      • 6) The homogenized mixture was poured into trays, to create thin films, which were refrigerated for 60 minutes.
      • 7) After cooling for 60 minutes, the films were place in a dehydrator at 40 C.
      • 8) The films were dried for 24 hours, to provide brittle, dry films.
      • 9) The dry films were broken into smaller pieces.
      • 10) 10 gram portions of the broken dried films were separated by size with a sieve to remove particles less than 15 mesh size.
      • 11) The collected particles were placed into a vacuum oven set to 40 C for 24 hrs, to provide finished dry granules.

Claims (25)

We claim:
1. A composition comprising:
a cannabinoid,
a surfactant, and
a carrier oil.
2. The composition of claim 1, comprising a sugar alcohol.
3. The composition of claim 1, comprising a gelling agent.
4. The composition of claim 1, comprising less than 10 mass % water.
5. The composition of claim 1, comprising more than 95 mass % water.
6. The composition of claim 1, comprising about 0.1 mg to about 10 mg of the cannabinoid.
7. The composition of claim 6, comprising about 0.5 mg to about 5 mg of the cannabinoid.
8. The composition of claim 1, wherein the composition is homogeneous.
9. The composition of claim 1, comprising a flavoring agent.
10. The composition of claim 1, comprising a coloring agent.
11. The composition of claim 1, comprising tea.
12. The composition of claim 11, wherein the tea is loose leaf tea.
13. The composition of claim 1, wherein the cannabinoid is chosen from THC and CBD.
14. The composition of claim 1, wherein the cannabinoid is THC.
15. The composition of claim 1, comprising cannabis oil.
16. The composition of claim 1, comprising at least two surfactants.
17. The composition of claim 16, comprising glycerol monostearate and polysorbate 80.
18. The composition of claim 1, comprising coconut oil.
19. The composition of claim 1, comprising less than 4 grams of caloric material.
20. The composition of claim 19, comprising less than about 2 grams of caloric material.
21. The composition of claim 7, wherein the 0.5 to 5 mg of the cannabinoid is present in a consistent amount, having less than 0.2 mg of deviation across sample portions of the composition.
22. The composition of claim 1, comprising:
cannabis oil having 1.5 to 3.5 mg of THC;
glycerine,
sorbitol,
gelatin,
glycerol monostearate,
polysorbate 80, and
coconut oil.
23. The composition of claim 22, comprising tea.
24. The composition of claim 22, comprising greater than 95 mass % water.
25. The composition of claim 22, comprising less than 5 mass % water.
US15/084,954 2015-05-18 2016-03-30 Homogenous cannabis compositions and methods of making the same Abandoned US20180007924A9 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2985332A CA2985332C (en) 2015-05-18 2016-03-30 Homogenous cannabis compositions and methods of making the same
US15/084,954 US20180007924A9 (en) 2015-05-18 2016-03-30 Homogenous cannabis compositions and methods of making the same
CA3176674A CA3176674A1 (en) 2015-05-18 2016-03-30 Homogenous cannabis compositions and methods of making the same
PCT/US2016/025044 WO2016186735A1 (en) 2015-05-18 2016-03-30 Homogenous cannabis compositions and methods of making the same
US16/571,610 US11980204B2 (en) 2015-05-18 2019-09-16 Cannabis compositions and methods of making the same
US18/340,572 US12225913B2 (en) 2015-05-18 2023-06-23 Cannabis compositions and methods of making the same
US18/963,286 US20250089735A1 (en) 2015-05-18 2024-11-27 Cannabis compositions and methods of making the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562163316P 2015-05-18 2015-05-18
US15/084,954 US20180007924A9 (en) 2015-05-18 2016-03-30 Homogenous cannabis compositions and methods of making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/571,610 Continuation US11980204B2 (en) 2015-05-18 2019-09-16 Cannabis compositions and methods of making the same

Publications (2)

Publication Number Publication Date
US20170280740A1 US20170280740A1 (en) 2017-10-05
US20180007924A9 true US20180007924A9 (en) 2018-01-11

Family

ID=57320177

Family Applications (4)

Application Number Title Priority Date Filing Date
US15/084,954 Abandoned US20180007924A9 (en) 2015-05-18 2016-03-30 Homogenous cannabis compositions and methods of making the same
US16/571,610 Active US11980204B2 (en) 2015-05-18 2019-09-16 Cannabis compositions and methods of making the same
US18/340,572 Active US12225913B2 (en) 2015-05-18 2023-06-23 Cannabis compositions and methods of making the same
US18/963,286 Pending US20250089735A1 (en) 2015-05-18 2024-11-27 Cannabis compositions and methods of making the same

Family Applications After (3)

Application Number Title Priority Date Filing Date
US16/571,610 Active US11980204B2 (en) 2015-05-18 2019-09-16 Cannabis compositions and methods of making the same
US18/340,572 Active US12225913B2 (en) 2015-05-18 2023-06-23 Cannabis compositions and methods of making the same
US18/963,286 Pending US20250089735A1 (en) 2015-05-18 2024-11-27 Cannabis compositions and methods of making the same

Country Status (3)

Country Link
US (4) US20180007924A9 (en)
CA (2) CA3176674A1 (en)
WO (1) WO2016186735A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020073032A1 (en) * 2018-10-06 2020-04-09 Capaldi Francesco Systems and methods of combining cannabinoids with a sugar-based solution and of creating orally dissolvable tablets
WO2020176806A1 (en) * 2019-02-27 2020-09-03 3-Delta, Inc. Compositions that contain lipophilic plant material and surfactant, and related methods
US11980204B2 (en) 2015-05-18 2024-05-14 5071, Inc. Cannabis compositions and methods of making the same
US12264296B2 (en) 2020-09-02 2025-04-01 Michael V. Zumpano Compositions that contain lipophilic plant material and surfactant, and related methods

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX390001B (en) * 2015-12-09 2025-03-19 Poviva Tea Llc STABLE READY-TO-DRINK BEVERAGE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS.
AU2018283411B2 (en) * 2017-06-16 2021-04-29 Sorse Technology Corporation Preparing stable liquid emulsion forms of plant extract
EP4356965A3 (en) * 2017-07-14 2024-07-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
WO2019018705A1 (en) * 2017-07-21 2019-01-24 Masaya World, Llc Cannabidiol-enriched caprylic acid
JP7438941B2 (en) 2017-10-30 2024-02-27 ウィスラー テクノロジーズ コーポレイション Methods and systems for terpene enrichment
CA3120213A1 (en) * 2018-11-30 2020-06-04 Canopy Growth Corporation Water-soluble formulations of cannabinoids or cannabis-derived compounds, methods of making and use
US20200352191A1 (en) * 2019-05-06 2020-11-12 Karl Lonsbery Edible formulations and uses thereof
US10919828B1 (en) * 2020-02-14 2021-02-16 Aicardo Roa-Espinosa Process for manufacturing cannabidiol
US11311559B2 (en) 2020-04-20 2022-04-26 Poviva Corp. Compositions and methods for enhanced delivery of antiviral agents
US20210329938A1 (en) * 2020-04-27 2021-10-28 Mikki West Cannabis beverage compositions
WO2021257935A1 (en) * 2020-06-19 2021-12-23 Lucas Naomie Nanoparticle-encapsulated cannabinoids and methods for making and using same
US20210393540A1 (en) * 2020-06-19 2021-12-23 NuRevelation, LLC Nanoparticle-encapsulated cannabinoids and methods for making and using same

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28919A (en) * 1860-06-26 Improvement in plows
US3506457A (en) 1965-02-25 1970-04-14 Pillsbury Co Agglomerated sugar products and method
DE3702029A1 (en) 1987-01-24 1988-08-04 Basf Ag AQUEOUS OR POWDERED, WATER-DISPERSIBLE PREPARATION OF A PHARMACEUTICAL ACTIVE SUBSTANCE IN WATER-SOLUBLE AND METHOD FOR THE PRODUCTION THEREOF
US4830862A (en) 1987-07-31 1989-05-16 The Procter & Gamble Company Calcium-supplemented beverages and beverage concentrates containing low levels of sulfate
US5284674A (en) 1992-05-11 1994-02-08 Fazio Susan C Powdered dairy creamer
US6197356B1 (en) 1993-08-03 2001-03-06 Immunopath Profile, Inc. Process for preparing hypoallergenic foods
US5554400A (en) 1994-08-25 1996-09-10 The Procter & Gamble Company Infusion beverage product comprising co-agglomerated creamer and sweetener suitable for bag and filter pack brewing
GB9625589D0 (en) 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6440449B1 (en) * 1998-01-15 2002-08-27 Edward Hirschberg Methods of infusing phytochemicals, nutraceuticals, and other compositions into food products
ZA200003120B (en) 1999-06-30 2001-01-02 Givaudan Roure Int Encapsulation of active ingredients.
DE60014255T2 (en) 1999-07-06 2005-11-03 Dsm Ip Assets B.V. Composition containing fat-soluble substances in a carbohydrate matrix
GB0015417D0 (en) 2000-06-24 2000-08-16 Cerestar Holding Bv Agglomerated starch-based product for food preparation
US6365176B1 (en) 2000-08-08 2002-04-02 Functional Foods, Inc. Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US6887493B2 (en) 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US20040234579A1 (en) 2003-05-22 2004-11-25 Mark D. Finke, Inc. Dietary supplements and methods of preparing and administering dietary supplements
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
WO2006012176A1 (en) * 2004-06-24 2006-02-02 Virginia Commonwealth University Water-soluble cannabinoids
ES2325039T3 (en) 2005-08-30 2009-08-24 Firmenich S.A. ENCAPSULATED ACTIVE INGREDIENTS, PREPARATION PROCEDURES AND YOURSELF.
MY147363A (en) 2005-09-20 2012-11-30 Nestec Sa Water dispersible composition and method for preparing same
US20070104741A1 (en) 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
US20140357708A1 (en) * 2005-11-07 2014-12-04 Murty Pharmaceuticals, Inc. Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
JP2009526033A (en) 2006-02-07 2009-07-16 オメガトリ エーエス Omega 3
EP2048965B1 (en) 2006-06-28 2015-02-11 Voyava Republic LLC A cold infusion process for fortifying coffee beans
JP2010503663A (en) 2006-09-15 2010-02-04 エコ・ファーマシューティカルズ・ビー.ブイ. Granules containing pharmaceutically active substance and method for producing the same
US20090095164A1 (en) * 2007-05-17 2009-04-16 Salvatore Albert Celeste Method of enhancing beverages by means of a unique microencapsulated delivery system
US20090162524A1 (en) 2007-12-21 2009-06-25 Tropicana Products, Inc. Food product including one or more omega-3 fatty acids and one or more fruit flavors
US20090264475A1 (en) 2008-01-24 2009-10-22 Schwartz Daniel M Methods and compositions for altering dietary behavior
EP2352497B1 (en) 2008-10-31 2017-02-22 University of Mississippi Process of preparation of delta-9-thc-amino acid esters
AR081323A1 (en) 2010-03-31 2012-08-08 Fonterra Co Operative Group PRODUCTION OF CONCENTRATED MILK FAT COMPOSITIONS AND HIGH DENSITY UNIFIED COMPOSITION
CN101904401A (en) 2010-07-09 2010-12-08 云南龙润茶业集团有限公司 Tea jelly sweet
US20120043242A1 (en) 2010-08-19 2012-02-23 Andrew David Hospodor Medicinal cannabis fatty foodstuff
US20120095087A1 (en) 2010-10-15 2012-04-19 Keith Hyatt Enhanced products by sustainable processes for medicinal use
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
WO2012106582A2 (en) 2011-02-03 2012-08-09 Snap Infusion Llc Confection composition
WO2012130278A1 (en) 2011-03-28 2012-10-04 Les Chocolats De L'iris S.A. Tea made of cacao-bean peels, and method for producing same
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
CA2848214A1 (en) 2011-09-08 2013-03-14 Rutgers, The State University Of New Jersey Production of enriched products
US20130164412A1 (en) 2011-12-23 2013-06-27 Udi Amrani Modified or infused cinnamon sticks for beverage and food use
US20130196022A1 (en) 2012-01-31 2013-08-01 Raisio Plc Milk and a process for its preparation
WO2013138906A1 (en) 2012-03-16 2013-09-26 Wright Jennifer Hemp-based infant formula and methods of making same
IN2014DN09507A (en) * 2012-05-03 2015-07-17 Echo Pharmaceuticals Bv
US8741341B2 (en) 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
US20130337113A1 (en) 2012-06-18 2013-12-19 George H. Clark Carbonated dairy nutrient beverage and method of making a carbonated dairy nutrient beverage to supply the same qualitative nutrition contained in skim milk to the human diet
US9345771B2 (en) * 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
CA2902722C (en) 2013-02-28 2022-07-12 SWM Luxembourg s.a.r.l. Composition for making a tea beverage or herbal and vegetable broths
CN103110582A (en) 2013-03-04 2013-05-22 上海医药工业研究院 Cannabis phenolic compound microemulsion and preparation method thereof
US20140370181A1 (en) 2013-03-15 2014-12-18 The Folger Coffee Company Coffee composition for use with a beverage unit and methods of using the same
WO2014186896A1 (en) 2013-05-22 2014-11-27 Earth's Own Food Company Inc Nut and dairy beverage
US20150035204A1 (en) * 2013-08-01 2015-02-05 Intertape Polymer Corp. Silicone adhesive tapes and method of masking using same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
WO2015024055A1 (en) 2013-08-20 2015-02-26 Deakin University Separation of omega-3 fatty acids
US9326967B2 (en) 2013-08-22 2016-05-03 Stephen C. Perry Vaporizable cannabinoid compositions
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
US9259449B2 (en) * 2014-01-07 2016-02-16 Joshua Michael Raderman Method for modifying THC content in a lipid-based extract of cannabis
US10071053B2 (en) * 2014-01-31 2018-09-11 Pocket Tea, Llc Tea composition for oral administration
US20170340562A9 (en) * 2014-05-12 2017-11-30 Hddc Holdings Llc Cannabinoid caffeinated drinks, powder, beans, and cannabinoid loose tea leaf
EP3152115B1 (en) * 2014-06-06 2021-05-05 Canntrust Inc. Method of preparing a single-serve beverage container containing cannabis
CA2949369C (en) 2014-06-11 2023-06-13 Poviva Tea, Llc Food and beverage compositions infused with lipophilic active agents and methods of use thereof
US10307397B2 (en) 2014-07-28 2019-06-04 Concept Matrix Solutions Oral dissolvable film that includes plant extract
US20160058866A1 (en) * 2014-09-02 2016-03-03 Ronald D. Sekura Alternative solutions for the administration of cannabis derived botanical products
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US20160143972A1 (en) 2014-11-21 2016-05-26 Cannamark Inc. Method and apparatus for preparing a solid form of cannabinoid
BR112017012434A2 (en) 2014-12-12 2018-02-20 Ojai Energetics Pbc microencapsulated cannabinoid compositions
US10238745B2 (en) * 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
US9629886B2 (en) 2015-02-24 2017-04-25 Ers Holdings, Llc Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil
WO2016144376A1 (en) * 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
CA3176674A1 (en) 2015-05-18 2016-11-24 5071, Inc. Homogenous cannabis compositions and methods of making the same
CA3003120A1 (en) 2015-10-26 2017-05-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoid formulations
US9937147B2 (en) 2015-10-29 2018-04-10 NBDD, Inc. Edible base product composition
CA2952335A1 (en) 2015-12-19 2017-06-19 Delta 9 Gardening B.V. Therapeutic delivery formulations and systems comprising cannabinoids and terpenes
EP3442522A4 (en) 2016-04-15 2020-01-01 SRE Wellness, Inc. Method of making cannabis oil hydrophilic using emulsifiers and related cannabinoid compositions
EP3463287A1 (en) 2016-05-27 2019-04-10 MedCan Pharma A/S Powdered composition comprising a complex between a cannabinoid and a basic ion exchange resin
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-emulsifying compositions of cannabinoids
EP3644986A4 (en) 2017-05-01 2021-01-06 MJ Wooly Corporation METHODOLOGY AND FORMULATION FOR THE PRODUCTION OF POWDER OF AN ENCAPSULATED, CANNABIS-BASED COMPONENT EMBEDDED IN A POLYMER MATRIX
AU2018283411B2 (en) 2017-06-16 2021-04-29 Sorse Technology Corporation Preparing stable liquid emulsion forms of plant extract
EP4356965A3 (en) 2017-07-14 2024-07-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
US20190240148A1 (en) 2018-02-07 2019-08-08 Tarukino Holdings, Inc. Lubricant composition and method for preparing the composition
US11192870B2 (en) 2018-03-07 2021-12-07 Socati Technologies—Oregon, Llc Continuous isolation of cannabidiol and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
US10414709B1 (en) 2018-12-14 2019-09-17 Socati Technologies Processes for solvent extraction of cannabinoids, terpenes and flavonoids from biomass
US10413845B1 (en) 2018-12-14 2019-09-17 Socati Technologies Processes for solvent extraction of cannabinoids, terpenes and flavonoids from biomass

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980204B2 (en) 2015-05-18 2024-05-14 5071, Inc. Cannabis compositions and methods of making the same
US12225913B2 (en) 2015-05-18 2025-02-18 5071, Inc. Cannabis compositions and methods of making the same
WO2020073032A1 (en) * 2018-10-06 2020-04-09 Capaldi Francesco Systems and methods of combining cannabinoids with a sugar-based solution and of creating orally dissolvable tablets
WO2020176806A1 (en) * 2019-02-27 2020-09-03 3-Delta, Inc. Compositions that contain lipophilic plant material and surfactant, and related methods
US12264296B2 (en) 2020-09-02 2025-04-01 Michael V. Zumpano Compositions that contain lipophilic plant material and surfactant, and related methods

Also Published As

Publication number Publication date
US20250089735A1 (en) 2025-03-20
US11980204B2 (en) 2024-05-14
US20200008441A1 (en) 2020-01-09
US20170280740A1 (en) 2017-10-05
WO2016186735A8 (en) 2017-06-01
US20230413845A1 (en) 2023-12-28
WO2016186735A1 (en) 2016-11-24
CA3176674A1 (en) 2016-11-24
US12225913B2 (en) 2025-02-18
CA2985332A1 (en) 2016-11-24
CA2985332C (en) 2023-01-03

Similar Documents

Publication Publication Date Title
US12225913B2 (en) Cannabis compositions and methods of making the same
Seal Quantitative HPLC analysis of phenolic acids, flavonoids and ascorbic acid in four different solvent extracts of two wild edible leaves, Sonchus arvensis and Oenanthe linearis of North-Eastern region in India
Abe et al. Comparison of phenol content and antioxidant capacity of nuts
Mateos et al. New lipophilic tyrosyl esters. Comparative antioxidant evaluation with hydroxytyrosyl esters
Kanmaz Subcritical water extraction of phenolic compounds from flaxseed meal sticks using accelerated solvent extractor (ASE)
Rao et al. Rapid extraction of andrographolide from Andrographis paniculata Nees by three phase partitioning and determination of its antioxidant activity
Cerda-Tapia et al. Valorization of pomace powder obtained from native Mexican apple (Malus domestica var. rayada): chemical, techno-functional and antioxidant properties
Okolo et al. Hexane extract of Dacryodes edulis fruits possesses anti-diabetic and hypolipidaemic potentials in alloxan diabetes of rats
CN103652859A (en) Health-care food with oxidation resistance and preparation method thereof
Abbas et al. Potential Role and Mechanism of Mulberry Extract in Immune Modulation: Focus on Chemical Compositions, Mechanistic Insights, and Extraction Techniques
Mann et al. Value addition scenario of arid foods of desert area and evaluation of their nutritional and phytochemical potential
Prajapati et al. Extraction and use of bioactive components from underutilized horticultural crops
Zompra et al. Metabolite and bioactive compounds profiling of meteora Sea buckthorn berries through high-resolution NMR analysis
EP3297617A1 (en) Homogenous cannabis compositions and methods of making the same
KR101153870B1 (en) Effective Perilla extract for inhibiting neuraminidase
AU2018338611A1 (en) Edible cannabinoid compositions
Nnadi et al. Antioxidant and antidiabetic potentials of a dimethoxylated flavone obtained from Helianthus annuus L. leaf extract
Abdallah et al. Useful bioactive compounds from olive tree by-products (Leaves, Branches, Fruits)
CN106065367A (en) Anti-oxidation edible oil and its preparation method and application
KR101868732B1 (en) Composition for extracting polyphenols and method for producing kenaf extract using thereof
JP2007526299A (en) Novel abietane diterpenoid compound and sputum extract, or composition for prevention and treatment of cardiovascular disease comprising as an active ingredient an abietane diterpenoid compound or terpenoid compound isolated therefrom
Aguree et al. Chemical Characterization of Crude Aqueous Extracts of Kigelia Africana Leaves and Cassia Sieberiena Root as Elephants’ Feeds Using GC-MS and FTIR
Ordaz-Trinidad et al. Patents on phytochemicals: methodologies of extraction, application in food and pharmaceutical industry
Hewageegana et al. Proximate analysis and standardization of leaves: Leptadenia reticulata (Retz) Wight and Arn (Jeevanti)
WO2021053259A1 (en) Method for extracting, from olive leaf, oleuropein in a phenolic fraction; functional food composition; and use

Legal Events

Date Code Title Description
AS Assignment

Owner name: 5071, INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOLDSTEIN, JEREMY H.;SINGER, JUSTIN ERIC;REEL/FRAME:038138/0547

Effective date: 20160330

AS Assignment

Owner name: 5071, INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VERWOLF, ADRIAN;NICODEMUS, GARRET;REEL/FRAME:042035/0827

Effective date: 20170306

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载